Terumo BCT showcases new CAR-T workflow enabling faster cell expansion
Ella Day | June 20, 2025 | News story | Manufacturing and Production | CAR-T cell manufacturing, Devices, EULV, Eureka Biotechnology, Terumo Blood and Cell Technologies, cell therapy, eureka, gene therapy
Terumo Blood and Cell Technologies (Terumo BCT) has unveiled a new automated workflow that consolidates three critical CAR-T manufacturing steps — T cell activation, viral transduction and expansion — into a single platform, streamlining production significantly. The protocol, published in Cytotherapy, uses the company’s quantum cell expansion system and demonstrates the potential to deliver over 12 billion CAR-T cells in just 7 to 8 days.
The streamlined process achieved a doubled increase in transduction efficiency over manual methods and supports the generation of vital T cell subtypes, including memory cells, which are crucial to therapy efficacy.
Developed in partnership with Eureka Biotechnology, the integrated workflow uses the spectra optia apheresis system for cell collection, Eureka’s cellsep pro for washing and its eulv platform for lentiviral vector production. Together, the tools form a closed, system using serum-free culture conditions to reduce contamination risks and variability.
“Our team developed this protocol with patients in mind and the goal of ensuring more people will have better access to the most effective therapies possible,” said Wenyan Leong, director of global strategic partnerships for cell and gene therapies at Terumo BCT. “We are excited to extend our expertise beyond cell collections by offering integrated solutions that support the entire cell therapy journey.”
Currently under evaluation by cell therapy developers, the 3-in-1 approach is expected to shorten timelines, lower costs, and expand patient access to CAR-T treatments. Terumo BCT will continue to build partnerships to advance scalable solutions for the cell and gene therapy sector.
Ella Day
20/6/25
Related Content
Major breakthrough in T-cell receptor therapy manufacturing
For the first time, researchers at the University of Chicago in the US have successfully …
ProteoNic Biosciences launches platform to enhance cell line productivity
ProteoNic Biosciences, a biotech company headquartered in Leiden, Germany has unveiled its latest technology platform, the …
Eyestem secures $10m to advance cell therapy for advanced eye disease
Indian cell therapy company, Eyestem Research, has raised $10m in a funding round to support …
